SAN DIEGO, Feb. 8 /PRNewswire-FirstCall/ -- Metabasis Therapeutics , announced today that Dr. Paul Laikind, president and chief executive officer of Metabasis will present at the BIO CEO & Investor Conference at The Waldorf-Astoria Hotel in New York City. Dr. Laikind is scheduled to present on Tuesday, February 13, 2007 at 12:45 p.m. Eastern Time, and is expected to provide an overview of the Company’s progress and discuss product candidates in clinical and pre-clinical development. The BIO CEO & Investor Conference company presentation will be webcast.
In addition, the Company announced that Dr. Paul Laikind will be a panelist at a metabolic therapeutic workshop at the BIO CEO & Investor conference. The session, entitled “Finding the Sweet Spot - New Approaches to Treating, Monitoring and Managing Diabetes”, is scheduled to take place on Wednesday, February 14, 2007 at 9:00 a.m. Eastern Time.
To access the live audio broadcast and the subsequent archived audio recording of the company presentation, please log onto the Company’s website at www.mbasis.com under the “Investors” section. The audio recording will be archived there for 30 days following the live presentation. Please connect to Metabasis’ website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary.
About Metabasis (www.mbasis.com):
Metabasis Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of novel drugs to address some of the world’s most widespread and costly chronic diseases involving pathways in the liver. The Company has established a pipeline that includes clinical stage and preclinical product candidates targeting major diseases with significant unmet medical needs. Targeted diseases include major metabolic diseases such as diabetes, hyperlipidemia and obesity as well as liver diseases such as hepatitis and primary liver cancer. Metabasis has developed several proprietary technologies for use in discovering and optimizing drugs, including the NuMimetic(TM) and HepDirect(R) technologies. Metabasis is continuing to identify and develop new product candidates using its proprietary technologies and expertise.
Metabasis Therapeutics
CONTACT: Constance Bienfait, Vice President of Investor Relations &Corporate Communications for Metabasis Therapeutics, Inc., +1-858-622-5575
Company News On-Call: http://www.prnewswire.com/comp/638776.html /
